	SIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	Annex G2
17	ICCVAM/NICEATM BG1Luc4E2 ER TA – Quantitative versus Qualitative
18	Assessment of Cell Viability
19	

November 8, 2010

DRAFT ICCVAM BRD – BG1Luc ER TA: Annex G2

DRAFT ICCVAM BRD – BG1Luc ER TA: Annex G2	November 8, 2010
PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	

[This page intentionally left blank]

33

November 8, 2010

DRAFT ICCVAM BRD – BG1Luc ER TA: Annex G2

DRAFT ICCVAM BRD – BG1Luc ER TA: Annex G2	November 8, 2010
PREDECISIONAL MATERIAL: DO NOT CITE, QUOTE, OR DISTRIBUTE	
-	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
[This page intentionally left blank]	
66	
67	
68	
69	

As part of the BG1LUC4E2 ER TA Bioassay protocol validation study, Xenobiotic Detection Systems, Inc. (XDS) evaluated the use Promega Corporation's CellTiter-Glo® quantitative cell viability assay. The assay measures cell viability based on the generation of luminescence signal proportional to the amount of ATP in viable cells. The CellTiter-Glo®assay requires the use of parallel plates as the luminescence signal interferes with the assessment of agonist or antagonist activity in the BG1LUC4E2 ER TA assay. The CellTiter-Glo® assay was conducted for all agonist and antagonist experiments during the BG1LUC4E2 ER TA assay protocol validation study. A qualitative method of assessing cell viability using visual observation previously developed by XDS was also conducted for all agonist and antagonist experiments during the BG1LUC4E2 ER TA assay protocol validation study. Criteria for assessing and scoring cell viability using XDS's visual observation method is provided in **Table 1**.

Table 1 Visual Observation Scoring Table

Viability Score	Brief Description ¹			
1	Normal Cell Morphology and Cell Density			
2	Altered Cell Morphology and/or Small Gaps between Cells			
3	Altered Cell Morphology and/or Large Gaps between Cells			
4	Few (or no) Visible Cells			
1P	Score of 1 with Precipitate			
2P	Score of 2 with Precipitate			
3P	Score of 3 with Precipitate			
4P	Score of 4 with Precipitate			
5P	Unable to View Cells Due to Precipitate			

A critical consideration in the conduct of the BG1LUC4E2 ER TA international validation study and the further standardization of the test method is the efficacy of limiting the assessment of cell viability to visual observation. This would greatly reduce the effort and cost of cell viability assessment by eliminating the need for running concurrent parallel plates required when using the CellTiter-Glo® method.

An initial examination of Raloxifene/E2 reference standard cell viability data using CellTiter-Glo® demonstrated that cell viability values of 80% or above did not correspond with a decrease in response in the BG1LUC4E2 ER TA assay. In general, CellTiter-Glo® values of 80% or above corresponded with a score of 1 in the visual observation method. Therefore, concentrations of test substance that caused a reduction in cell viability below 80% using CellTiter-Glo® or that had viability scores of 2 or more in the visual observation method were classified as cytotoxic and these data were not used to assess ER activity in the BG1LUC4E2 ER TA protocol standardization study.

In the protocol standardization study, CellTiter-Glo® results from the testing of eight substances covering a range of antagonist activities were compared to results from the XDS visual observation method (for discussion purposes, comparison of results is for

104 antagonist testing only because it is critical to distinguish whether reduction of 105 luminescence is based on cytotoxicity or reduced ER mediated transcriptional activity). 106 107 In **Tables 2-6** below, selected results from five of the eight substances tested are provided 108 as information to facilitate a discussion regarding the efficacy of limiting the assessment 109 of cell viability to visual observation. 110 111 Table values highlighted in green indicate visual observation scores that did not correspond with CellTiter-Glo® % cell viability values (i.e., % cell viability of 80% or 112 113 above should correspond to a visual observation score of 1). 114 Table values highlighted in blue indicate concentrations of substance that had acceptable 115 116 cell viability as assessed by CellTiter-Glo® and would have been used to assess ER 117 antagonist activity in the BG1LUC4E2 ER TA assay but would not have been used if 118 assessment of cell viability was limited to visual observation. 119 120 "% Reduction of E2" is defined as the ability of a given concentration of test substance to reduce the ER TA activity induced by the E2 control (2.5 x 10⁻⁵ µg/mL, a concentration 121 122 of E2 that induces 80-90% of maximum ER TA in the test system). 123 124

Butylbenzyl phthalate (Table 2) - classified as negative for antagonism in BRD.

126

4/12/06 experiment:

- 127 **4**/128
- CellTiter-Glo® values and visual observation scores correspond

129 130 Concentrations reducing E2 activity classified as cytotoxic, so not used to assess ER activity

131

• Classified as negative for ER antagonist activity

132133

4/15/06 experiment:

134

• CellTiter-Glo® values and visual observation scores correspond

135 136 No concentrations reducing E2 activity classified as cytotoxic, so used to assess ER activity

137

• Classified as positive for ER antagonist activity

138 139

4/18/06 experiment:

140141

• CellTiter-Glo[®] values and visual observation scores do not correspond at concentrations of $2.50 \times 10^{+1}$ and $1.25 \times 10^{+1} \mu g/mL$

142143

• Concentrations reducing E2 activity classified as cytotoxic by either CellTiter-Glo® or visual observation, so not used to assess ER activity

144145

• Classified as negative for ER antagonist activity but would have been classified as positive if using visual observations only

146147

 Table 2
 Butylbenzyl phthalate

Date	Conc. μg/mL	% Reduction of E2	% Cell Viability	Visual Observation
4/12/06	$5.00 \times 10^{+1}$	67	76	2
4/12/06	$2.50 \times 10^{+1}$	24	74	2
	$5.00 \times 10^{+1}$	83	84	1
4/15/06	$2.50 \times 10^{+1}$	68	82	1
	$1.25 \times 10^{+1}$	24	83	1
4/18/06	$5.00 \times 10^{+1}$	44	75	2
	$2.50 \times 10^{+1}$	35	70	1
	$1.25 \times 10^{+1}$	8	74	1

Flavone (Table 3) - classified as positive for antagonism in BRD (in all studies).

151

4/12/06 experiment:

152153

• CellTiter-Glo® values and visual observation scores did not correspond

154155

Concentrations reducing E2 activity classified as cytotoxic by either CellTiter-Glo® or visual observation, so not used to assess ER activity

156157

• Classified as negative for ER antagonist activity but would have been classified as positive if using visual observations only

157 158 159

4/15/06 experiment:

160 161 • CellTiter-Glo® values and visual observation scores do not correspond at 5.00 x 10⁺¹ µg/mL

162 163 • Concentrations reducing E2 activity (2.50 x 10⁺¹ and 1.25 x 10⁺¹ μg/mL) not classified as cytotoxic, so used to assess ER activity

164

Classified as positive for ER antagonist activity

165

4/18/06 experiment:

166167168

CellTiter-Glo[®] values and visual observation scores do not correspond at concentrations of $2.50 \times 10^{+1}$ and $1.25 \times 10^{+1} \,\mu\text{g/mL}$

169 170 Concentrations reducing E2 activity classified as cytotoxic by either CellTiter-Glo[®] or visual observation, so not used to assess ER activity

171 172 • Classified as negative for ER antagonist activity but would have been classified as positive if using visual observations only

173 174

Table 3 Flavone

Date	Conc. µg/mL	% Reduction of E2	% Cell Viability	Visual Observation
	$5.00 \times 10^{+1}$	93	83	2
4/12/06	$2.50 \times 10^{+1}$	72	78	1
4/12/00	$1.25 \times 10^{+1}$	38	78	1
	$6.25 \times 10^{+0}$	9	85	1
4/15/06	$5.00 \times 10^{+1}$	99	91	2
	$2.50 \times 10^{+1}$	90	86	1
	$1.25 \times 10^{+1}$	37	85	1
	$6.25 \times 10^{+0}$	0	86	1
4/18/06	$5.00 \times 10^{+1}$	77	74	2
	$2.50 \times 10^{+1}$	66	75	1
	$1.25 \times 10^{+1}$	16	79	1

Nonylphenol (Table 4) - classified as positive for antagonism in BRD (in only one study).

179 180

181

182 183

4/15/06 experiment:

- CellTiter-Glo® values and visual observation scores correspond
- 1.25 x 10⁺¹ μg/mL concentration reducing E2 activity classified as cytotoxic, so not used to assess ER activity
- Classified as positive for ER antagonist activity at 6.25 x 10⁺⁰ μg/mL

184 185 186

187 188

189

4/20/06 experiment:

- CellTiter-Glo® values and visual observation scores correspond
- Concentrations reducing E2 activity classified as cytotoxic, so not used to assess ER activity
- Classified as negative for ER antagonist activity

190 191 192

193

194 195

5/01/06 experiment:

- CellTiter-Glo® values and visual observation scores correspond
- 1.25 x 10^{+1} µg/mL concentration reducing E2 activity classified as cytotoxic, so not used to assess ER activity
- Classified as positive for ER antagonist activity at $6.25 \times 10^{+0} \,\mu\text{g/mL}$

197 198 199

196

Table 4 Nonylphenol

Date	Conc. µg/mL	% Reduction of E2	% Cell Viability	Visual Observation
4/15/06	$1.25 \times 10^{+1}$	99	29	4
	$6.25 \times 10^{+0}$	44	82	1
4/20/06	$1.25 \times 10^{+1}$	99	29	3
	$6.25 \times 10^{+0}$	61	75	2
5/01/06	$1.25 \times 10^{+1}$	99	64	3
	$6.25 \times 10^{+0}$	34	84	1

Progesterone (**Table 5**) - classified as negative for antagonism in BRD.

203204

4/15/06 experiment:

205

• CellTiter-Glo® values and visual observation scores correspond

206207

 Neither concentration reducing E2 activity classified as cytotoxic, so used to assess ER activity

207 208

• Classified as positive for ER antagonist activity

209210

4/20/06 experiment:

211212

• CellTiter-Glo® values and visual observation scores do not correspond at 1.25 x $10^{+1}\,\mu g/mL$

213

Concentrations reducing E2 activity ($2.50 \times 10^{+1}$ and $1.25 \times 10^{+1} \,\mu\text{g/mL}$) classified as cytotoxic, so not used to assess ER activity

214215

Demonstrates "borderline" ER antagonist activity at 6.25 x 10⁺⁰ μg/mL

216 217

5/01/06 experiment:

218

• CellTiter-Glo® values and visual observation scores correspond

219220

 Concentrations reducing E2 activity classified as cytotoxic, so not used to assess ER activity

221222

Classified as negative for ER antagonist activity

223 224

Table 5 Progesterone

Date	Conc. µg/mL	% Reduction of E2	% Cell Viability	Visual Observation
4/15/06	$1.25 \times 10^{+1}$	73	86	1
	$6.25 \times 10^{+0}$	39	92	1
4/20/06	$2.5 \times 10^{+1}$	99	62	2
	$1.25 \times 10^{+1}$	61	72	1
	6.25 x 10 ⁺⁰	20	93	1
5/01/06	2.5 x 10 ⁺¹	87	62	3
	$1.25 \times 10^{+1}$	49	69	3

227 *o,p*'-DDT (Table 6) - classified as positive for antagonism in BRD (for one study).

228

4/20/06 experiment:

- 229230
- CellTiter-Glo® values and visual observation scores correspond

231232

 Concentrations reducing E2 activity classified as cytotoxic, so not used to assess ER activity

233

Classified as negative for ER antagonist activity

234235

5/01/06 experiment:

236

• CellTiter-Glo® values and visual observation scores correspond

237238

 Concentrations reducing E2 activity classified as cytotoxic, so not used to assess ER activity

239

• Classified as negative for ER antagonist activity

240241

5/05/06 experiment:

242243

• CellTiter-Glo® values and visual observation scores do not correspond at 1.25 x $10^{+1} \, \mu g/mL$

244245

• Concentrations reducing E2 activity classified as cytotoxic by visual observation but not at 1.25 x 10⁺¹ µg/mL with CellTiter-Glo[®]

246247248

• Classified as negative for ER antagonist activity when using visual observations only but would have been classified positive for antagonism at $1.25 \times 10^{+1} \,\mu\text{g/mL}$ with CellTiter-Glo®

249

250251

Table 6 o,p'-DDT

Date	Conc. μg/mL	% Reduction of E2	% Cell Viability	Visual Observation
	$5.00 \times 10^{+1}$	99	19	4
4/20/06	$2.50 \times 10^{+1}$	99	45	4
	$1.25 \times 10^{+1}$	40	75	2
5/1/06	$5.00 \times 10^{+1}$	99	26	4
	$2.50 \times 10^{+1}$	99	59	4
	$1.25 \times 10^{+1}$	22	74	2
5/5/06	$5.00 \times 10^{+1}$	99	20	4
	$2.50 \times 10^{+1}$	87	60	3
	1.25 x 10 ⁺¹	29	82	2